Literature DB >> 27365222

Evaluation of the route dependency of the pharmacokinetics and neuro-pharmacokinetics of tramadol and its main metabolites in rats.

Behjat Sheikholeslami1, Mahdi Gholami2, Hoda Lavasani3, Mohammadreza Rouini4.   

Abstract

Tramadol hydrochloride is a centrally acting analgesic used for the treatment of moderate-to-severe pain. It has three main metabolites: O-desmethyltramadol (M1), N-desmethyltramadol (M2), and N,O-didesmethyltramadol (M5). Because of the frequent use of tramadol by patients and drug abusers, the ability to determine the parent drug and its metabolites in plasma and cerebrospinal fluid is of great importance. In the present study, a pharmacokinetic approach was applied using two groups of five male Wistar rats administered a 20mg/kg dose of tramadol via intravenous (i.v.) or intraperitoneal (i.p.) routes. Plasma and CSF samples were collected at 5-360min following tramadol administration. Our results demonstrate that the plasma values of Cmax (C0 in i.v. group) and area under the curve (AUC)0-t for tramadol were 23,314.40±6944.85 vs. 3187.39±760.25ng/mL (Cmax) and 871.15±165.98 vs. 414.04±149.25μg·min/mL in the i.v. and i.p. groups, respectively (p<0.05). However, there were no significant differences between i.v. and i.p. plasma values for tramadol metabolites (p>0.05). Tramadol rapidly penetrated the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB) (5.00±0.00 vs. 10.00±5.77min in i.v. and i.p. groups, respectively). Tramadol and its metabolites (M1 and M2) were present to a lesser extent in the cerebrospinal fluid (CSF) than in the plasma. M5 hardly penetrated the CSF, owing to its high polarity. There was no significant difference between the AUC0-t of tramadol in plasma (414.04±149.25μg·min/mL) and CSF (221.81±83.02μg·min/mL) in the i.p. group. In addition, the amounts of metabolites (M1 and M2) in the CSF showed no significant differences following both routes of administration. There were also no significant differences among the Kp,uu,CSF(0-360) (0.51±0.12 vs. 0.63±0.04) and Kp,uu,CSF(0-∞) (0.61±0.10 vs. 0.62±0.02) for i.v. and i.p. pathways, respectively (p>0.05). Drug targeting efficiency (DTE) values of tramadol after i.p. injection were more than unity for all scheduled time points. Considering the main analgesic effect of M1, it is hypothesized that both routes of administration may produce the same amount of analgesia.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Blood brain barrier; CSF; N-desmethyltramadol (PubChem CID:198555); O-desmethyltramadol (PubChem CID:130829); Tramadol; Tramadol (PubChem CID:33741); Unbound drug concentration

Mesh:

Substances:

Year:  2016        PMID: 27365222     DOI: 10.1016/j.ejps.2016.06.021

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  6 in total

1.  Identification of canine cytochrome P-450s (CYPs) metabolizing the tramadol (+)-M1 and (+)-M2 metabolites to the tramadol (+)-M5 metabolite in dog liver microsomes.

Authors:  Tania E Perez Jimenez; Katrina L Mealey; Darren Schnider; Tamara L Grubb; Stephen A Greene; Michael H Court
Journal:  J Vet Pharmacol Ther       Date:  2018-08-16       Impact factor: 1.786

2.  Clinical Management of Pain in Rodents.

Authors:  Patricia L Foley; Lon V Kendall; Patricia V Turner
Journal:  Comp Med       Date:  2019-12-10       Impact factor: 0.982

3.  Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive Inhibition.

Authors:  Tao Long; Rodrigo Cristofoletti; Brian Cicali; Veronique Michaud; Pamela Dow; Jacques Turgeon; Stephan Schmidt
Journal:  J Clin Pharmacol       Date:  2021-09-20       Impact factor: 2.860

4.  Activation of the P2X7 receptor in midbrain periaqueductal gray participates in the analgesic effect of tramadol in bone cancer pain rats.

Authors:  Pengtao Li; Quan Zhang; Zhi Xiao; Shouyang Yu; Yan Yan; Ying Qin
Journal:  Mol Pain       Date:  2018-09-10       Impact factor: 3.395

5.  Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome.

Authors:  Anna Rickli; Evangelia Liakoni; Marius C Hoener; Matthias E Liechti
Journal:  Br J Pharmacol       Date:  2018-01-06       Impact factor: 8.739

6.  Tramadol's Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.

Authors:  Diana C Esquivel-Franco; Berend Olivier; Marcel D Waldinger; Gabriel Gutiérrez-Ospina; Jocelien D A Olivier
Journal:  Front Pharmacol       Date:  2018-06-27       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.